Copertina

Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Michael A. Nauck, Viktoria Punov, Yu Mi Kang, Soo Lim
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials
di: Yu Mi Kang, et al.
Pubblicazione: (2025)

Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes?
di: Cristina Bianchi, et al.
Pubblicazione: (2026)

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
di: Elias John Elenjickal, et al.
Pubblicazione: (2026)

Incretin mimetics for weight loss forgive nonadherence
di: Anıl Cengiz, et al.
Pubblicazione: (2025)

Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed‐Dose Titration of Weekly Insulin Efsitora in Insulin‐Naïve Type 2 Diabetes
di: Lisa Connery, et al.
Pubblicazione: (2026)

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model
di: Lee‐Ling Lim, et al.
Pubblicazione: (2026)

Incretin‐based therapy and the risk of diabetic foot ulcers and related events
di: Nikki C. C. Werkman, et al.
Pubblicazione: (2024)

Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study
di: Ali Kapan, et al.
Pubblicazione: (2026)

Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study
di: Jun Hwa Hong, et al.
Pubblicazione: (2026)

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study
di: Kuo‐En Chen, et al.
Pubblicazione: (2026)

A Physiological Model of Incretin‐Based Therapies and Hierarchical Energy Allocation Across Metabolic Phenotypes
di: Christine Stier, et al.
Pubblicazione: (2026)

Low‐Dose Glucagon After Fasted Morning Exercise in People With Type 1 Diabetes—A Randomised Crossover Comparison of Low and High Carbohydrate Diets
di: Signe Schmidt, et al.
Pubblicazione: (2026)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
di: Karen L. Jones, et al.
Pubblicazione: (2024)

Pathway‐Specific Polygenic Risk Scores and Cardiorenal Complications in Asians With Type 2 Diabetes
di: Resham L. Gurung, et al.
Pubblicazione: (2026)

Young People With Type 2 Diabetes Are Under‐Represented in Randomized Clinical Trials
di: Bowei Yu, et al.
Pubblicazione: (2026)

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study
di: Assaf Issachar, et al.
Pubblicazione: (2026)

Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
di: Minji Sohn, et al.
Pubblicazione: (2024)

Type 2 Diabetes and the Glucagon Renaissance: Restoring Bihormonal Equilibrium
di: Abdelilah Arredouani
Pubblicazione: (2026)

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study
di: Taweesak Wannachalee, et al.
Pubblicazione: (2026)

Enriched Metabolic Phenotyping Refines Phenotypic Resolution of Type 2 Diabetes
di: Min Wang, et al.
Pubblicazione: (2026)

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
di: Jan Oscarsson, et al.
Pubblicazione: (2026)

Waist‐to‐Height Ratio and the Risk of Cardiovascular Outcomes and Mortality in Type 2 Diabetes With and Without Abdominal Obesity
di: Kye‐Yeung Park, et al.
Pubblicazione: (2026)

Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials
di: Thomaz Alexandre Costa, et al.
Pubblicazione: (2025)

Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison
di: Ji Eun Jun, et al.
Pubblicazione: (2026)

Polygenic Risk Score Predicts Prostate Cancer Risk Independent of Type 2 Diabetes
di: Guk Jin Lee, et al.
Pubblicazione: (2026)

Cardiorenal Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus With Nephrotic‐Range Proteinuria: A Multi‐Institutional Target Trial Emulation
di: Jia‐Jin Chen, et al.
Pubblicazione: (2026)

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes
di: Christine Ljungberg, et al.
Pubblicazione: (2026)

Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes
di: Zhenxi Wang, et al.
Pubblicazione: (2026)

The One‐Hour Oral Glucose Tolerance Test to Predict Glucose Intolerance Postpartum in Women With Prior Gestational Diabetes
di: Niels Bochanen, et al.
Pubblicazione: (2026)

Optimising the Therapeutic Window: A Systematic Review and Network Meta‐Analysis of Pregabalin Dosing Strategies for Painful Diabetic Neuropathy
di: Doyun Kwon, et al.
Pubblicazione: (2026)

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis
di: João Sérgio Neves, et al.
Pubblicazione: (2026)

Equivalent Acute Anti‐Inflammatory Effects of Exercise in Type 2 Diabetes Versus Healthy Adults: A Randomised Crossover Study
di: Yu‐Min Huang, et al.
Pubblicazione: (2026)

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes ( ONWARDS 10): A Randomised Controlled Trial
di: Julio Rosenstock, et al.
Pubblicazione: (2026)

Teplizumab in Stage 2 Type 1 Diabetes: Clinical Practice Experience on Feasibility in 3 Adult Patients
di: V. Guarnotta, et al.
Pubblicazione: (2026)

Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States
di: Neda Al Rawashdh, et al.
Pubblicazione: (2026)

Estimated Glucose Disposal Rate and Risk of Vascular Events and Death in Type 2 Diabetes in the ADVANCE Study
di: Ruirui Wang, et al.
Pubblicazione: (2026)

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function
di: Hiroki Nobayashi, et al.
Pubblicazione: (2026)

Interrelationship Between Baseline HbA1c , SGLT ‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis
di: Samuel Seidu, et al.
Pubblicazione: (2026)

Coexisting Asthma and Diabetes Are Associated With Adverse Metabolic and Inflammatory Profiles
di: Sixtus Aguree, et al.
Pubblicazione: (2026)

Exercise Metabolic Flexibility in Type 2 Diabetes Treated With Empagliflozin: An Exploratory Analysis of the Randomised Trial EMPA ‐ HEART
di: Lorenzo Nesti, et al.
Pubblicazione: (2026)